The primary role of Feldegel (Piroxicam gel) plays a role in managing the overall symptom load of localized pain and inflammation, contributing to improved comfort across several common musculoskeletal conditions.

The gel is suitable for application in scenarios where symptoms that interfere with daily functioning have appeared suddenly. This symptomatic assistance may assist with managing the symptom burden in conditions like muscle strains, ligament sprains, contusions (bruises), tendinitis, and bursitis.

The symptomatic relief offered is focused on addressing the localized discomfort and inflammatory signs at the site of application.

Targeted Relief and Symptomatic Support

Feldegel is applied in situations involving acute, benign trauma and localized inflammatory processes. It is also considered relevant for providing symptomatic assistance in managing pain and stiffness in specific, localized osteoarthritis (OA) of peripheral joints. Applied across domains where additional symptomatic support is needed, this topical formulation supports the patient during difficult symptomatic phases, such as episodes of heightened discomfort during an inflammatory flare-up.

---

Quick Fact: Relief for Localized Pain and Swelling

---

Regulatory References

1. Health Products Regulatory Authority (HPRA) Product Information

The official regulatory labeling for Feldegel defines specific population groups who are either contraindicated or must use the product under severe restrictions.

Who is Contraindicated (Must Not Use)

Feldegel is strictly contraindicated for any individual with a known hypersensitivity to the active ingredient, Piroxicam, or to any of its excipients. Absolute prohibition also applies to patients who have experienced asthma, urticaria, or other allergic reactions triggered by aspirin or any other Non-Steroidal Anti-Inflammatory Drug (NSAID). Use is contraindicated for women beginning from the sixth month of pregnancy (beyond 24 weeks gestation).

Age and Population Restrictions

The product is not recommended for use in children under 12 years of age, as its safety and efficacy have not been established in the pediatric population. Older adults should proceed with particular care. The medicine is also not recommended for women who are breastfeeding or actively attempting to conceive.

Conditional Use and Specific Limitations

Use requires extreme caution in patients with a current or historical diagnosis of peptic ulcer, active gastrointestinal bleeding, or active inflammatory disease of the gastrointestinal tract. Caution is also advised for patients with severe renal or hepatic impairment. Feldegel must not be applied to broken, infected, or open skin lesions.

The official regulatory profile for Feldegel (Piroxicam gel) documents potential interactions based on the active ingredient’s classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID), even though systemic interactions are generally considered unlikely due to the very low plasma levels achieved after topical application.

Interaction-Related Restrictions

Co-administration with other NSAIDs, whether topical or systemic, is formally advised against to prevent additive systemic risks. Similarly, co-use with analgesic doses of Aspirin is not recommended.

Official Interaction Statements

The documented interaction statements primarily cover the potential for Exposure-Modifying and Pharmacodynamic effects should systemic absorption occur:

• Exposure-Altering Agents: Piroxicam has the potential to cause decreased elimination of substances such as Lithium and Methotrexate, potentially increasing their plasma concentrations. The product may also increase the serum concentration of Digoxin.
• Pharmacodynamic Risks: Potential exists for the anticoagulant effect of Coumarin-type medicines like Warfarin to be potentiated. Concurrently, Piroxicam may diminish the therapeutic effects of Anti-hypertensives and Diuretics.
• Metabolic Interactions: Regulatory information states a risk of inhibiting the metabolism of Oral Hypoglycaemic Agents (Sulfonylurea drugs).
• Substance Notes: The official documentation notes that alcohol intake increases the risk of serious gastrointestinal bleeding when combined with NSAIDs. Interaction risks are specified as being more significant in elderly patients and those with impaired renal function.

Blocking the Cyclooxygenase (COX) Enzyme

The mechanism involves the modulation of chemical signaling sequences active during localized physiological responses. The action is confined to the site of application and relies on inhibiting a critical enzyme responsible for generating specific mediators. Piroxicam, the active component, is a non-selective inhibitor that binds reversibly to the Cyclooxygenase (COX) enzyme. This action halts the enzyme's ability to process its natural substrate, Arachidonic Acid, limiting the subsequent formation of Eicosanoids.

---

Suppression of Prostaglandin Synthesis and Signaling

The immediate physiological consequence of enzyme blockade involves altered mediator production. By inhibiting COX, the drug rapidly reduces the local synthesis and release of Prostaglandins ( PGE2, PGI2), which are chemical mediators. Lowered prostaglandin concentration leads to two key physiological changes: a reduction in local vascular permeability and a decreased sensitization of peripheral nerve endings (nociceptors).

---

Localized Alteration of Nociceptor and Vascular Dynamics

The molecular cascade results in a predictable physiological effect. The focused reduction in Prostaglandins alters the local inflammatory cascade. This alters the chemical environment of the affected tissue, resulting in suppressed nociceptor signaling and reduced fluid extravasation. This mechanism is entirely dependent on sufficient transdermal delivery to the affected underlying tissue.

How to Use Feldegel: Administration Guidelines

Feldegel (Piroxicam 0.5% Gel) is administered via the cutaneous route for external use on the skin. This application method is intended to ensure consistent delivery of the active ingredient to the affected area.

---

Administration Schedule and Dose

Instruction	Description
Route of Administration	Strictly External Use Only (Cutaneous route).
Standard Dose	1 gram of 0.5% gel per application. This amount is equivalent to a strip approximately 3 cm long.
Frequency Pattern	Applied to the affected area three or four times per day

---

Procedural and Contextual Instructions

The use of Feldegel involves specific handling requirements. The gel must be rubbed into the application site until no residual material remains on the skin, and an occlusive dressing must not be employed over the treated area. Additionally, the gel must be kept away from the eyes and mucous membranes.

For the elderly population, the approach is to utilize the lowest dose compatible with adequate control. Use in the paediatric population is not established or generally recommended. The course of treatment should be reviewed by a clinician if no clinical benefit is observed after four weeks of continuous use. This protocol defines the steps for the use of the product.

Research evidence / Overview of studies for Feldegel

---

Evidence for Localized Osteoarthritis of Peripheral Joints

Research exploring Piroxicam gel was primarily conducted in Randomized Controlled Trials (RCTs) and Systematic Reviews for conditions such as localized osteoarthritis (OA). These trials focused on superficial joints like the knee, examining patient-reported outcomes for discomfort and daily functioning. Measurements of change in pain were typically monitored over intermediate time intervals of 4 to 12 weeks. Other analyses described differing effect estimates for functional improvement when compared against non-NSAID or placebo formulations that were studied in similar contexts.

Evidence for Acute Soft Tissue Injuries

The core evidence for this topical gel in conditions associated with acute episodes, such as muscle strains, ligament sprains, and tendinitis, is derived from short-term RCTs. This research explored symptom changes over defined time intervals, typically lasting only 3 to 14 days. Studies monitored outcomes including the change in spontaneous pain and pain on movement. Research also notes that the high response rate observed in the placebo groups—attributed to the self-limiting nature of these acute injuries—contributes to the difficulty in interpreting final pain measurements.

Follow-up, Special Populations, and Research Gaps

Long-term outcomes following the typical study durations are not fully established, as the evidence base provides little insight into the durability of reported changes over many months. The results apply only to the populations studied, meaning there is limited information regarding the gel's use on deeper, non-superficial joints. While the medication was observed in studies that included older adults, data for pediatric populations remain insufficient, and comparative evidence is often lacking regarding broad conclusions about different formulations.

Key Studies & References Health Products Regulatory Authority (HPRA) Product Information: Felden Piroxicam 0.5% Gel

Common questions about Feldegel (FAQ)

Q: Is Feldegel the same type of medicine as ibuprofen or aspirin?

Feldegel’s active ingredient, Piroxicam, is classified by regulatory authorities as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This is the same general classification as both ibuprofen and aspirin. Official warnings state that the gel should not be used by individuals who have experienced allergic reactions, such as asthma or hives, after taking oral NSAIDs like aspirin.

Q: Are there any long-term side effects associated with using Feldegel?

Regulatory documents list potential side effects based on clinical data, including a note that the highest risk period for very rare, serious skin reactions is within the first weeks of treatment. For effectiveness, the full course is directed to be reviewed by a clinician after four weeks of continuous use if no benefit is observed. The evidence base provides limited insight into long-term outcomes.

Q: Is it safe to use Feldegel while pregnant or breastfeeding?

Official documentation specifies that Feldegel is contraindicated—meaning it must not be used—starting from the sixth month of pregnancy (beyond 24 weeks gestation). Furthermore, the product is not recommended for use by women who are breastfeeding, since clinical safety has not been established in this population.

Q: Is Feldegel appropriate for children or only adults?

According to official product information, Feldegel is not recommended for use in children under 12 years of age. This is because the safety and effectiveness of the gel have not been sufficiently established or studied in the pediatric population.

Q: Do studies suggest Feldegel is more effective for certain types of injuries than others?

Research evidence primarily addresses the use of Piroxicam gel for two main conditions: localized osteoarthritis (OA) of superficial joints and acute soft tissue injuries like sprains and strains. Official documents describe the results and effect estimates for each type of condition based on the specific populations studied in these clinical trials.

Q: Do older adults (seniors) have different safety considerations for Feldegel?

Official instructions state that for older adults, the lowest dose compatible with adequate control should be utilized. Regulatory information also notes that the potential for drug interactions, particularly with other systemic medications, is specified as being more significant in the elderly population.

Q: Do official documents mention any potential interactions with alcohol?

Official documentation includes a general NSAID-class warning noting that alcohol intake increases the risk of serious gastrointestinal bleeding when combined with NSAIDs taken by mouth. This information is included in the topical product’s profile as a general safety consideration associated with the drug class.

Q: Why is Feldegel a gel formulation instead of a cream or patch?

Feldegel is specifically formulated as a gel to allow for the transdermal delivery of the active ingredient, Piroxicam, through the skin. This specific formulation is described in official sources as enabling focused action for localized symptomatic relief via direct application to the affected tissue.

Q: What happens if I use Feldegel more often than recommended on the label?

Official instructions advise against using the product for a longer time, more often, or more than the dose specified. Regulatory sources indicate that systemic side effects are unlikely with topical use; however, exceeding instructions increases the potential for unwanted effects.

Q: What should I do if I accidentally swallow some Feldegel?

Regulatory guidance describes that immediate contact with a local Poison Information Centre or seeking medical attention is required if the product is accidentally swallowed. This instruction applies even if no immediate symptoms or signs of discomfort are apparent.

Q: Does sun exposure change the risk profile of Feldegel use?

Official documents list photosensitivity skin reactions—an increased sensitivity to sunlight—as a possible documented occurrence. To address this risk, regulatory documents advise protecting treated areas from strong sunlight and avoiding artificial UV sources like sunbeds during treatment.

Q: Why do official guidelines mention limiting the duration of Feldegel use?

Official guidelines indicate that a full course of treatment should be reviewed by a clinician if no benefit is observed after four weeks of continuous use, which is linked to the extent of established evidence. The limit is in place to ensure a healthcare professional determines if a clear clinical benefit has been observed.

Q: Can Feldegel affect laboratory blood test results?

While the gel has low systemic absorption, the full regulatory profile for its active ingredient, Piroxicam, notes that blood and urine tests may be required to check for unwanted effects when the drug is used systemically for long periods. The potential for the NSAID drug class to interact with other substances, which could affect lab test results, is noted in the official documentation.

Q: What is the difference in how Feldegel works compared to capsaicin creams?

Feldegel works by reversibly inhibiting the Cyclooxygenase (COX) enzyme. According to official documents, this action suppresses the local synthesis of Prostaglandins—chemicals that cause inflammation—to reduce localized pain. This is the mechanism by which its anti-inflammatory and analgesic effects are achieved.

Storage and Disposal Requirements for Feldene Gel

Official regulatory documents define strict rules for the storage and disposal of Feldene Gel (piroxicam 0.5% gel) to maintain its integrity and ensure public safety.

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 30 C and do not freeze.
Protection	Keep the product in its original tube and protected from light.
Safety	It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Feldene Gel must not be thrown away with household trash or via wastewater. According to regulatory instructions, patients should consult a pharmacist for the proper disposal of unused medicinal products. Following authorized disposal procedures is necessary to protect the environment.